Cardinal Health buys GI Alliance and Advanced Diabetes Supply Group for about $3.9 bln
Cardinal Health said on Monday it acquired majority stakes in GI Alliance and Advanced Diabetes Supply Group (ADSG) for about $2.8 billion and $1.1 billion each in an all cash deal.
Cardinal Health Q1 Earnings: Margins Signal More Upside
Cardinal Health's Q1 2025 earnings reaffirm my buy rating due to a strengthening pharmacy business and industry tailwinds. Despite initial market overreaction to 2025 guidance, Cardinal Health's management is transparently mitigating risks. A DCF analysis suggests a price target of $128 for CAH stock, offering a 17% upside.
Cardinal Health, Inc. (CAH) Soars to 52-Week High, Time to Cash Out?
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardinal Health Stock Hits All-Time High as Existing Customers Power Results
Cardinal Health (CAH) shares hit a new all-time intraday high Friday as the healthcare products provider posted better-than-expected results and raised its outlook even as it took a financial hit from the ending of a big contract.
Cardinal Health, Inc. (CAH) Q1 2025 Earnings Call Transcript
Cardinal Health, Inc. (NYSE:CAH ) Q1 2025 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Erin Wright - Morgan Stanley Eric Percher - Nephron Research Allen Lutz - Bank of America Kevin Caliendo - UBS Eric Coldwell - Baird George Hill - Deutsche Bank Stephanie Davis - Barclays Elizabeth Anderson - Evercore ISI Daniel Grosslight - Citi Charles Rhyee - TD Cowen Stephen Baxter - Wells Fargo Operator Hello, and welcome to the First Quarter Fiscal Year 2025 Cardinal Health, Incorporated Earnings Conference Call. My name is George, and I'll be your coordinator for today's event.
CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View
Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.
Here's What Key Metrics Tell Us About Cardinal (CAH) Q1 Earnings
The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
Cardinal Health (CAH) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.73 per share a year ago.
Cardinal Health lifts annual profit outlook on strength in specialty medicines unit
Cardinal Health raised its 2025 adjusted profit forecast on Friday as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit, sending the shares of the company up nearly 4% in premarket trading.
Exploring Analyst Estimates for Cardinal (CAH) Q1 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cardinal (CAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Cardinal Health (CAH) closed at $110.87, indicating a -0.02% shift from the previous trading day.
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
